Allitinib NEW
| Price | $48 | $113 | $185 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Allitinib | CAS No.: 897383-62-9 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Allitinib |
| Description | Allitinib (AST-1306) (AST-1306) has anti-cancer activity,and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. [1] |
| In vitro | AST1306 (AST-1306; 0.19-6.25 μM; 72 hours) inhibits the growth of HIH3T3-EGFR T790M/L858R cells[1]. AST1306 (0.001-1.0 μM; 4 hours) is more than 3000-fold selective for ErbB family kinases over other kinase families[1]. In A549, Calu-3, and SK-OV-3 cells, AST1306 inhibits tyrosine kinase activation and downstream signaling pathways, and dose-dependently and markedly inhibits EGF-induced EGFR phosphorylation in A549 cells[1]. |
| In vivo | AST1306 (AST-1306; oral; 25-100 mg/kg) significantly inhibited tumor growth in SK-OV-3 and Calu-3 xenograft models[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 67.5 mg/mL (150.37 mM), Sonication is recommended. 10% DMSO+90% Saline : < 6.75 mg/mL (15.04 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 6.75 mg/mL (15.04 mM), Suspension. |
| Keywords | Irreversible | Inhibitor | inhibit | HER1 | ErbB4 | ErbB2 | ErbB-1 | Epidermal growth factor receptor | EGFRL858R/T790M | EGFR (T790M/L858R) | EGFR | AST1306 | AST 1306 | anti-cancer | anilino-quinazoline | ALS-1306 | ALS1306 | Allitinib |
| Inhibitors Related | (S)-Afatinib | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Afatinib | Chalcone | Brigatinib | Genistein | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY